PHATPhathom Pharmaceuticals, Inc.
Price
-34%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market against it.
Charts
As reported to the SEC, without any scoring.
Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $74M in Q2 2026 (quarter ended Jun 30, 2026), up 88% from the same quarter a year earlier. That came with a gross margin of 80% and net loss of $18M. For the full year FY2025, revenue was $175M (+217% year on year) and net income −$221M. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive …Other event · Form 8-K
- Jul 30, 2026Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 23, 2026On June 23, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA ® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (“EoE”) in adults.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.